BACKGROUND: Nosocomial pneumonias are common in trauma patients and so interventions to prevent and treat nosocomial pneumonia may improve outcomes. Our prior work strongly suggests that tissue injury predisposes to infections like nosocomial pneumonia because mitochondrial debris originating from injured cells contains damage-associated molecular patterns that can reduce neutrophil (PMN) migration into the airway and diminish PMN function in response to bacterial inoculation of the airway. This suggested that putting exogenous "normal" PMN into the airway might be beneficial.
T rauma is the leading cause of death in the younger than 45 years age group and the third leading cause of death in all populations. 1 Nosocomial pneumonia is a common cause of morbidity and death in trauma patients. [2] [3] [4] [5] Thus, prevention of nosocomial pneumonia would contribute significantly to reducing the morbidity and cost of injury. Early after injury, trauma patients are susceptible to "community-acquired" pneumonias (CAP), that are commonly thought to arise from the patient's endogenous oropharyngeal flora that are inoculated into the airway due to early transient loss of airway protective reflexes. Early CAP is typically caused by gram-positive organisms. Later, patients who remain ill or endotracheally intubated are at risk for "hospital-acquired" or "healthcare-acquired" pneumonias (HAP). These are commonly caused by gram-negative organisms or resistant gram-positive organisms that colonize the patient over time, especially in the presence of antibiotics. Thus, common HAP pathogens include Pseudomonas aeruginosa (PA) and methicillin-resistant Staphylococcus aureus. Although it has been widely assumed that pneumonia after injury is a function of increased airway inoculation and suppressed bacterial clearance due to poor cough, these suppositions are unsupported, 6 and it is now clear that suppression of innate immunity by injury is a critical and primary determinant of infection after trauma.
The immunologic links between injury itself and nosocomial pneumonia are still very poorly understood, but neutrophils (PMN) are the predominant effector cells protecting the airway from infection. Addressing that issue, we have clearly shown that damage-associated molecular patterns (DAMPs) emanating from injured tissue are capable of placing distant sites like the lung, at risk for infection by bacterial inocula that would otherwise be ineffective. 7 Mitochondria-derived DAMPs (mitochondrial debris [MTD] ) released from injured tissues predispose to pneumonia, at least in part, by reducing PMN recruitment to the lungs. 7, 8 But we suspect that PMN failure to protect the lung against inoculation may reflect suppressed PMN function as much as failure to marginate at the host-airway interface after trauma.
This novel mechanistic understanding may be important in several ways. First, it suggests that we should be looking for ways to augment innate immunity, thus decreasing the establishment of inoculated bacteria and preventing pneumonia. Second, it suggests augmenting innate immunity may allow us to treat pneumonias that are resistant to antibiotics. Third, nonantibiotic methods of decreasing the incidence of pneumonia after injury may allow us to decrease the emergence of antibiotic resistance in the first instance. To achieve our aims, we chose to both explore the molecular biology of suppressed inmate immunity and at the same time to look for novel therapies that reverse or bypass inmate immune failure. In this set of investigations, we explore the possibility that replacing endogenous suppressed PMN with exogenous normal PMNs can prevent or reverse establishment of bacterial growth in the lung after injury. To do that, we used our established models of injury combined with intratracheal (i.t.) inoculation of S. aureus (SA) to model early, gram-positive CAP, and P. aeruginosa (PA) to model late, gram-negative HAP. Cell-based therapies using PMN could also be totally independent of antibiotics and thus could become a new and highly desirable form of prevention and/or treatment for posttraumatic pneumonia.
MATERIALS AND METHODS

Animals
All animal experimental procedures were approved by Institutional Animal Care and Use Committee at Beth Israel Deaconess Medical Center. Seven-to 9-week-old CD-1 mice were kept at our animal care facility with 12-hour light/dark cycles with free access to water and standard food. Animals were allowed to acclimatize for at least a day before being used for experimental procedures.
Bacterial Strains
Staphylococcus aureus Rosenbach (S. aureus, gram-positive, ATCC 14458) and P. aeruginosa (Schroeter) Migula (P. aeruginosa, gram-negative, ATCC 10145) and were purchased from American Type Culture Collection (ATCC, Manassas, VA) and used by following the supplier's protocol. Briefly, bacteria were kept at −80°C. Prior to use, bacteria were grown in 100 mL of Bacto Agar medium (Becton Dickinson) overnight. Then 1 mL of bacteria containing medium was applied to 100 mL of fresh agar medium for 2 hours. Bacteria were then spun down at 4,500 rpm for 10 minutes at 4°C. Finally, bacteria were resuspended in sterile phosphate-buffered saline (PBS) to OD600 = 0.1. This protocol results in an inoculum of 5 Â 10 6 colony forming units (CFU) in 50 μL (as confirmed by direct count).
Bone Marrow-Derived PMN
Bone marrow-derived PMN (BM-PMN) were freshly isolated from the femurs of donor animals, such as CD-1 or C57BL/ 6 mice as described by Swamydas et al. 9 Cells were suspended in sterile saline to a concentration of approximately 2 Â 10 6 in 50 μL. We confirmed that BM-PMN were functionally active by showing that they increased their intracellular calcium levels and chemotaxis in response to N-Formyl-Met-Leu-Phe (fMLP). Also, we validated their functional activity by showing they respond to bacteria with phagocytosis and PMN extracellular trap formation (data not shown). Other groups have reported similar functions of BM-PMN. 10, 11 It has also been shown that each BM-PMN can ingest up to 100 S. aureus or E. coli in 30 minutes in vitro. 12, 13 Thus, theoretically, 10 4 PMN should be able to kill 10 6 bacteria, and we therefore elected to apply this higher number of BM-PMN per bacteria in in vivo experiments.
DAMPs Preparation and Injury Modeling
To model systemic exposure to DAMPs similar to those seen after abdominal injury, we used intraperitoneal (i.p.) injection of sonicated MTD isolated from 10% of a CD-1 mouse liver. We have previously shown that the DAMPs present in this amount of mitochondria (MT) affect systemic PMN responses in a way that is indistinguishable from that caused by crushing 10% of the mouse's liver at laparotomy or by injection of morcellated mouse liver (10% of the animal's estimated liver weight) into the peritoneal cavity at laparotomy. Our methods for isolating MT and preparing MTD from mouse liver are published in detail elsewhere.
14,15
Intratracheal Instillation
Mice were anesthetized with a combination of Ketamine (100 mg/kg) and xylazine (20 mg/kg). Tracheal intubation and infusion was performed using the protocol described by Cai and Kimura. 16 The mice are placed on a vertical support. We then place a 22G plastic catheter (sterile, single use, Fisher Scientific) in the trachea. We apply experimental solutions to the top (hub) of the catheter and wait (typically 2-3 minutes) until the fluids are fully inhaled as a result of the animal's own respiratory efforts. The total volume of each PMN and bacterial inoculum (and/or the saline vehicle controls) was 50 μL. As soon as the solutions are inhaled into the lung, the catheters are removed, the animals are returned to their cages and placed on heating pads until they are mobile. Critically, we apply all experimental solutions passively through inhalation via the catheter without using a syringe to force the materials into the lung. This method guarantees that all applied materials go i.t. and is also less stressful to the animals. 16 
Bronchoalveolar Lavage Fluid and Lung Homogenates
Bronchoalveolar lavage fluid (BALF) was obtained after sacrifice by application of 1 mL sterile PBS through a 30G catheter secured into the trachea and used to gently irrigate the lungs. For whole-lung homogenates, lungs were isolated, placed in 5 mL of ice-cold PBS and homogenized in a Stomacher 80 (Seward, UK). Twenty microliters to 100 μL of freshly isolated BALF or lung homogenates were then applied to tryptic soy agar plates to determine bacterial counts. Note that separate animals were used for BALF and lung homogenization experiments.
Experimental Protocols
For each experiment, we randomly divided CD-1 mice into three experimental groups. Establishment of early-onset and lateonset pneumonia after injury (CAP and HAP, respectively) were modeled by inoculation of S. aureus and P. aeruginosa in the presence of injury modeled by i.p. injection of mitochodrial DAMPs (mtDAMPs). Protocols can be found in Figure 1. 1. Prevention of early-onset pneumonia (see Fig. 1 , timeline A): group 1 (bacteria-only) had 0.9% NaCl (saline) injected i.p. at T = 0 and bacteria (S. aureus, SA, 1 Â 10 6 CFU in 50-μL saline) injected i.t. at T = 3 hours (n = 8 animals). Group 2 (DAMPs + bacteria) got MTD (isolated from 10% of a CD-1 mouse liver) i.p. at T = 0 and then were inoculated with SA i.t. at T = 3 hours. n = 8 animals. Group 3 (PMN rescue) got MTD i.p. at T = 0, SA i.t. at T = 3 hours and BM-PMN (2 Â 10 6 in 50 μL saline from CD-1 mice) i.t. at T = 6 hours (n = 9 animals). Animals were sacrificed at T = 24 hours. Bacterial clearance was assayed by culturing BALF or lung homogenates on Tryptic Soy Agar plates to evaluate bacterial clearance (CFU) (see Fig. 2 ). 2. Prevention of late-onset pneumonia (see Fig. 1 , timeline B):
CD-1 mice were assigned to groups as in the early-onset pneumonia experiments. Rather than staphylococcus (SA), in this case, mice were inoculated with PA. Also, we performed the bacterial inoculations somewhat later to reflect the later clinical timing of inoculation by gram-negative hospital acquired bacteria. Thus here, group 1 got saline-injected i.p. at T = 0 and bacteria (PA, 1 Â 10 6 CFU in 50 μL saline) injected i.t. at T = 24 hours (n = 10 animals). Group 2 got MTD i.p. at T = 0 and PA i.t. at T = 24 hours (n = 11 animals). Group 3 got MTD i.p. at T = 0, bacteria i.t. at T = 24 hours, and BM-PMN (2 Â 10 6 in 50 μL saline) i.t. at T = 27 hours (n = 12 animals). All animals were sacrificed at T = 48 hours, and bacterial clearance was evaluated as above. Aliquots of lung homogenates were applied to Tryptic Soy Agar plates to evaluate bacterial clearance (CFU) as above. Similarly, we applied more bacteria (CFU, OD600 = 0.111) to evaluate the role of external PMN application on bacterial clearance (see Fig. 3 ). 3. Prevention of late onset of pneumonia with increased number of P. aeruginosa. Either saline (group 1, controls) or mtDAMPs (group. 2 and 3) were given i.p. at T = 0. At T = 24 hours, all groups had P. aeruginosa (OD600 = 0.111, 5 Â 10 6 CFU i.t. in 50 μL) instilled i.t. (note 5Â higher PA dose than experiments 1 and 2). Three hours later, BM-PMN (2 Â 10 6 cells) were applied i.t. in group 3 only. At 24 hours after bacterial inoculation, all animals were sacrificed to evaluate bacterial clearance in lung as discussed below. Number of animals used for groups 1, 2, and 3 were 4, 6, and 8, respectively (see Fig. 4 ). 4. Evaluation of potential lung injury due to PMN instillation.
First, PMN from CD-1 mice (or saline) were instilled i.t. in CD-1 mice given i.p MTD plus i.t. P. aeruginosa. Then, cross-instillation of CD-1 PMN into BL6 mice and vice versa was performed. BALF samples were collected from the mice at 24 hours as described above. Protein concentrations in the BALF samples were examined as a marker for lung damage caused by the various treatments. Protein concentrations were determined by BCA protein assay (ThermoFisher) where each samples were evaluated in triplicates (see Fig. 5 ). Data analysis and power calculations and mice number estimation: Data were analyzed by one-way analysis of variance (ANOVA) analysis with Tukey's post hoc test using SigmaPlot 13.1 statistical software (Systat Software, Inc.) to evaluate for significant differences. Our preliminary results suggest that mean bacterial numbers for mtDAMPs + bacteria and mtDAMPs + bacteria + PMN were 5,600 and 1,300, respectively. Also, standard deviations were 4,000 and 700, respectively. Power analysis calculations using SigmaPlot 13.1 show that samples from eight mice of each group would provide approximately 80% power to detect differences in true mean value of each treatment at the p = 0.005 level of significance. Similarly, we used at least eight mice per group for other experiments. Numbers of animals were modified depending on data we obtained.
Mean and SD values were also shown.
RESULTS
1. Intratracheal Instillation of PMN prevents establishment of early gram (+) pneumonia after injury. We tested whether the number of PMN and function in lungs at the time of infection might be crucial for gram (+) bacterial clearance. We analyzed three mouse groups: (1) i.p. saline + i.t. bacteria (n = 8); (2) i.p. mtDAMPs + i.t. bacteria (n = 8); and( 3) i.p. mtDAMPs + i.t. bacteria + i.t. PMN (n = 9). The number in each bracket represents the number of animals used.Three hours after i.p. injection of mtDAMPs or saline (vehicle), bacteria (S. aureus, 5 Â 10 6 CFU/50 μL) was applied. Another 3 hours later, PMN (2 Â 10 6 cells) were applied i.t. in group 3. Twenty-four hours after bacteria infusion, we examined the lung for bacterial clearance.In prior work, 8 we showed that exposure to mtDAMPs in fractures decreased clearance of SA from the airspaces. We see again that systemic exposure to DAMPs (in this case, MTD given i.p. to model abdominal injury) reduced SA clearance from whole lung homogenates (p = 0.047, Fig. 2 . This was again reproduced in BALF analysis. In each case, i.t.-PMN returned clearance of the SA inoculum after i.p. MTD administration to the level of controls (no MTD, p = NS). These data show that i.t. PMN administration can restore normal pulmonary clearance of gram-positive bacteria, thus preventing establishment of early onset, post-traumatic pneumonia in an animal system where abdominal trauma has been modeled by administration of i.p mtDAMPs. 2. Intratracheal instillation of PMN prevents establishment of late gram (−) pneumonia after injury. We tested whether the number of PMN and function in lungs at the time of infection might be crucial for gram (−) bacterial clearance. We analyzed three analogous mouse groups (Fig. 3 ). These were different in that the time points used for experimentation were somewhat later so as to better reflect the evolution of late, hospital acquired pneumonia (HAP). The gram (−) PA (OD600 = 0.1; 5 Â 10 6 CFU in 50 μL) was instilled i.t. 24 hours after mtDAMPs were given i.p. In group 3 BM-PMN (2 Â 10 6 cells) were applied i.t. 3 hours later. 24 hours after bacterial inoculation animals were sacrificed to evaluate bacterial clearance from the lung as previously. Similar to early S. aureus infection, the saline/bacteria group (n = 10) showed complete bacterial clearance from the lung (Bar 1). The group given MTD i.p. before bacteria group (n = 11, bar 2) showed very limited bacterial clearance. But the group given MTD and bacteria followed by PMN (n = 12, bar 3) showed near complete bacterial clearance very similar to that seen in Saline/Bac. Clearance was significantly different than the MTD/Bac group (p = 0.038). The number in each bracket represents the number of animals used. 3. Intratracheal Instillation of PMN can treat gram (−) pneumonia after injury. Because results one and two above showed that PMN could prevent establishment of CAP and HAP after injury, we next examined whether exogenous PMN could prevent pneumonia from becoming established after a dose of bacteria that was sufficient to cause pneumonia in the absence of injury. We thus applied more bacteria intratracheally (PA, 50 μL of OD600 = 0.111) and as shown in Figure 4 , P. aeruginosa at this higher dose is not cleared spontaneously does not increase lung leak. Infusion of BM-PMN was found to have no adverse effects on lung leak when using PMN from the same strain of mouse (Figs. 2 and 3) . Next, we evaluated whether instillation of BM-PMN between different strains of mice caused changes in permeability as measured by changes in BALF total protein levels. This is important for the design of future mechanistic studies as well as for future treatment options since it infers that xenograft PMN might be used this way therapeutically. We therefore prepared BM-PMN from C57BL/6 and CD-1 mice and instilled them intratracheally into CD-1 and C57BL/6 mice, respectively. Seventy-two hours after i.t. installation, BALF specimens were prepared to evaluate alveolar protein concentrations as a marker for lung injury. As controls, CD-1 mice were instilled with saline i.t. (n = 5) or BM-PMN i.t. from CD-1 mice (n = 5) and BALF specimens were collected 24 hours after instillation. In addition, CD-1 mice were injected with MTD (10% liver, i.p.) followed by S. aureus i.t. and Hepes buffered saline solution (HBSS) (n = 3) or BM-PMN (both i.t.) (n = 3). As shown in Figure 5 not only saline and BM-PMN from CD-1 but an exchange of BM-PMN between strains (n = 2 each) did not induce any lung injury (~300 μg/mL). As expected, bacterial infection did cause lung injury (1,200 μg/mL) but instillation of exogenous PMN did not increase it (~1,200 μg/mL). BALF protein in controls and all PMN exchanges were all significantly less than that seen in bacterially infected mice. Note that even increasing the number of PMN infused (up to 2.75 million) between different strains did not cause any damage to the lungs. The number in each bracket represents the number of animals used. Note that BALF from each animal was evaluated for protein concentration in triplicates. Thus, we compared "mean and SD data" from at least six individual results.
DISCUSSION
Trauma patients in intensive care units and especially those with abdominal injuries are at high risk for developing infections, and nosocomial pneumonias are common in this population. 17 Historically, this predilection to pneumonia has been attributed to contamination of the lung by loss of airway reflexes to aspiration related to endotracheal intubation and to poor pulmonary toilet due to pain from injury or needed operations, but these assertions are unproven. 6 We show here that exogenous PMNs delivered via the airway can protect against early CAP as well as late HAP after injury. We also find tantalizing early data suggesting that airway-delivered PMN may be used to attack established gram-negative pneumonias directly since PMN application effectively cleared increased number of gram (−) bacterial infection that could not be cleared in uninjured animals. In addition, our data showed that PMN exchange between two different strains of mice does not induce any lung injury, suggesting that PMN from animals such as pigs may be used to humans in the future.
Mitochondria originated as bacterial endosymbionts, 18 so when they are released from injured tissues, they present specific N-formylated peptides and mitochondrial DNA (mtDNA) species to the innate immune system. These DAMPs modulate systemic immune function. 7, 8, 14, 15, 19, 20 Mitochondria also contain n-formyl peptides that are powerful PMN chemoattractants Even though only two animals were used for some conditions, each BALF was evaluated for protein assay in triplicates. Thus, statistical analysis is trustworthy since we are using at least six numbers to obtain "mean and SD values." via the formyl peptide receptors (FPRs). 21 [24] [25] [26] These responses all play important roles in bacteria killing. 14 Moreover, mtDAMPs activate monocytes/macrophages, leading to further production of chemoattractants at local injury sites. Thus, mtDAMPs can elicit chemoattractant gradients to injury sites, causing PMN to migrate preferentially to sites of injury. We have shown that liver injuries, fractures (experimental pseudofractures), and i.p. injection of damaged MT (MTD) all act as injury models, attracting PMN to sites of injury. 8 Furthermore, we have shown that exposure to formyl peptides originating from clinical injury makes PMN less sensitive to lung-derived chemokines. 7 Accordingly, after injury, we see decreased innate immune and PMN response to bacterial colonization of the lung. 27, 28 Gram-negative bacteria are increasingly resistant to available antibiotics, and some strains are resistant to most or all available treatments. S. aureus is also a common cause of resistant bacterial infections after trauma. 29, 30 These events increase morbidity and mortality from bacterial infections and thus to higher health care costs. 29 Moreover, no new antibiotics are expected in the near future. 31, 32 Thus, cell-based, nonantibiotic therapies may become vital for treatment of posttraumatic pneumonias. Also, if increased susceptibility to pneumonia after injury reflects the exhaustion of PMN function after partial activation, broad-based therapies to prevent or treat infection could be directed at recruiting functionally active PMN to the airway or blocking receptors (like FPR-1) that increase PMN migration to and activation at sites of injury.
In conclusion, we investigated the association between tissue injury and distant infections and established that when mtDAMPs are released from damaged tissues PMN activity in the lung is suppressed. This suppression can be overcome directly by instilling functional PMNs into the airway in the mouse. Our results suggest that PMN instillation prevents bacterial colonization but does not prove its effectiveness on established pneumonia. We will further investigate the effectiveness on established pneumonia by delaying PMN instillation. Large animal models including primate will be used before we can consider such therapies in humans, but the use of exogenous immune cells to bolster the innate immune resistance of the airway to infection after injury is an exciting possibility.
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DISCUSSION
Dr. Ronald V. Maier (Seattle, Washington): I thank the organization for the opportunity to discuss this superb paper, which gives us a lot to think about. If they are correct, this truly may cause a paradigm shift in our clinical approach.
It's a well-done study, and I do not argue with their methodology. However, the use of non-injection of the endotracheal tube with passive inhalation by the animal, rather than forcing bacteria into the lungs, is a unique technique that hopefully will prevent iatrogenic-induced lung injury.
We have long known that endotoxin massively activated the innate immune system, including the neutrophil and causes SIRS, multiple organ failure; and we postulate endotoxin as clinically important for mortality in the ICU. The critical problem with this paradigm for 30 years was why or how does sterile trauma cause SIRS and multiple organ failure. As recently pointed out, danger molecules, including mitochondrial DNA, released during tissue injury can cause innate immune signaling similar to endotoxin and cause the same massive activation of the innate immune system and subsequent organ failure.
Both tissue injury and stimulated PMNs caused by many different stresses cause this extra-cellular release of mitochondrial DNA, both as part of the innate immune response and as a more passive effect from the injured tissue. However, it's not clear which source of DNA is more important and which contributes most to the clinical pathology. However, the concept is supported by what we have seen in the Glue Grant genome-wide studies with a simultaneous, massive up-regulation of a pro-inflammatory response and simultaneous suppression of adaptive immunity.
The current study deals with the suppressive component of this modulation of the immune system. The question is how we can avoid the secondary impact of nosocomial infections. The authors show that mitochondrial DNA suppresses neutrophil function, which they have confirmed and that there is an increase in both early and late pneumonias (actually colonizations) in their model.
The exciting data are they can correct this functional defect merely by adding normal neutrophils via the trachea of these animals; an amazing simplistic concept. Sometimes the simplest concepts are the most important in improving patient care. They reconstitute normal anti-bacterial function and produce nonantibiotic treatment for "recent onset pneumonia", a fantastic advance in consideration of the problems with bacterial resistance and other issues.
I have several questions to help understand the data. You propose using recently obtained unstimulated neutrophils to treat infection and compensate for the endogenous defective neutrophils. However, if your model based on the released mitochondrial DNA is correct, inactivating the host DNA should also be protective, why not just ehance clearance of the extracellular mitochondrial DNA, and avoid the need and associated problems with using biologic products, such as neutrophils to humans? If your theory is correct that the mitochondrial DNase that normally clears mitochondrial DNA is decreased, why not just replete DNase, prevent the mitochondrial DNA stimulation of neutrophils, subsequent suppression of activity and pneumonia? Thus, clinically patients should do well without having to expose them to exogenous or xenogeneic neutrophils.
In addition, what is the timing of this process? Once neutrophil suppression occurs from exposure to mitochondrial DNA, does immune-suppression last for the lifetime of the neutrophil? Does the suppression last only while the mitochondrial DNA is present with the neutrophil? Is it a temporary or permanent effect? If you remove the DNA, does the neutrophil recover function?
Second, is this suppressive process unique to mitochondrial DNA, or can any of numerous stimuli following trauma cause the same problem? Does an episode of aspiration or a brief bout of sepsis that causes up-regulation of neutrophils cause the same suppressive changes in neutrophil function, similar to mitochondrial DNA, or is it unique to exposure to the mitochondrial DNA? Do you have any data to help understand the underlying cell biology?
Third, you also use a very large number of neutrophils in your model to compensate for the neutrophil suppression. When you go to larger animal models where are you going to obtain neutrophils? Are you planning to use control donor for neutrophils? Obtain them from the blood bank? Are blood bank preserved neutrophils still functional? Or do you plan to use a xenogenic source?
We have spent years trying to take neutrophils out of banked blood to prevent activated neutrophils from making patients ill. You are now proposing that we should intentionally load neutrophils via the endotracheal tube to make patients better. Are you convinced of the safety of this approach?
Lastly, how do you know this immunosuppression is not evolutionarily protective? Do you have data that evolutionarily, after being hit by a truck, neutrophils should not be suppressed? If you eliminate the suppression of neutrophils, will you increase bystander cellular injury and organ failure? This concern may be worse, particularly if you give neutrophils too early in the response, similar to dumping gasoline on a fire of innate immunity over-expression, with the new neutrophils being overstimulated and contributing to the SIRS and multiple organ failure.
Overall, this simplistic concept proposes to directly correct a major immune deficit, treat infection without antibiotics and avoiding resistance and potentially have a significant clinical impact on the care of our patients. I hope that Dr. Hauser and your team is able to move this concept to clinical trial. Thank you.
Dr. Joseph Cuschieri (Seattle, Washington): Just to expand a little bit on what Dr. Maier asked in regard to the neutrophils that were exposed to mitochondrial DNA, you exposed them to the bacteria three hours after the mitochondrial DNA was administered. So with a lifespan of a neutrophil of over five days, do you hypothesize that you are going to have the same duration of effects? In other words, how long to you predict the protective changes will be present?
The second thing is in regard to when you instilled your neutrophils. You instilled your neutrophils three hours after your exposure to your bacteria. Now, clinically, it is hard to predict exact timing when a patient develops pneumonia and it usually takes a day or so to figure it out. Are you going to have the same effect if you administer neutrophils a day later rather than three hours after installation of bacteria?
Dr. Luke Leenan (Utrecht, Netherlands): When I understand correctly this is an acute experiment lasting 48 hours. Now, when you install new neutrophils the lifetime of neutrophils is about six days. There is new evidence now that these neutrophils can eat bacteria, however, they don't kill it. And there you have it, at the end of the lifecycle, a freeing up of those intracellular bacteria.
So how do you know that these bacterial are adequately eaten up and also killed-so not only erased from the system but also actually killed?
Dr. Kiyoshi Itagaki (Boston, Massachusetts): Thank you, Dr. Maier, for your very kind comments. As to whether we can skip mitochondria, MT were simply used to model traumadependent pneumonia. Certainly other forms of injury can lead to pneumonia. And we suspect that danger signaling may play a similar role there. Although we are grateful you have enough enthusiasm to suggest we skip ahead to human trials, we doubt this could be justified without prior studies in first small and then large animals.
As to treatments with DNase, there are DNases in the circulation that clear mitochondrial DNA rapidly, but not rapidly enough it seems to prevent its action. Application of DNase may cause serious side effects by degrading other important DNA. Alternatively, mtDNA is also a marker for other danger molecules, both mitochondrial (like formyl peptides) and nonmitochondrial. So giving DNases to break down mtDNA is not going to be enough.
The points about the dynamics of this process are well taken and we need to study this. But since PMN are terminally differentiated we think that the suppression that occurs from exposure to MT-DAMPs is likely to be permanent. But then of course new PMN are constantly produced by the bone marrow.
As to other means of regaining neutrophil function, we are studying those as well. It remains to be seen however whether giving some systemic drug that for instance blocks inflammatory signaling is safer than simply replacing neutrophils since they seem so benign given in this way.
Is this process unique to mitochondrial DNA? Perhaps instead, the question should be whether mtDAMPs are unique to trauma. In the aspiration example you pointed to, we found that acid lung injury gives rise to enormous amounts of intra-alveolar mitochondrial DNA [collaboration with Dr. Brahm H. Segal, PMCID: PMC3563868]. Viral lung injury may cause similar danger signaling.
So far, the number of PMN used may seem large, but the sources are nearly limitless, especially in humans and large animals, where 1 million PMN can be obtained from 1 mL of blood. So figuring out the logistics of obtaining PMN for allotransplantation is way in the future. But no matter what, it's easier than developing new antibiotics. Has the last 20 years of studies have been totally wasted? Probably not: after all, we've learned a lot about PMN biology and it's brought us to this point. You're right that hyper-activated circulating PMN will attack the lung. But does that mean that hyper-activated circulating PMN will attack bacteria in the alveoli? Maybe it's a case of "the right place but the wrong time". In any case, the fact that we've been looking at it all backwards shouldn't seem too strange. After all, we used to think the sun went around the earth, too!
We also agree with all of your comments about the potential for PMN given this way to cause problems and that timing, dose and location of therapy will be critical to obtaining the right balance between SIRS and infection. Perhaps that's exactly why we shouldn't jump straight to human trials.
Dr. Cuschieri, to be exact, we did not give mitochondrial DNA i.p. We gave a slurry of sonicated mitochondria, or mtDAMPs. This is important since it contains numerous other DAMPs. Also, the half-life of PMN is very short although it goes up with inflammation and the suppression of apoptosis, but the key issue is that this is a model. We have generated novel models of early Gram-positive pneumonia and later Gram negative-pneumonia to approximate human susceptibility to clinical infection after injury. In the next couple of years we'll generate all of the nuanced data that you're asking about, but even then it will still be in mice. When we go to large animals and man I'm sure that we will find the timing of events to be different in every species. What surprised us is that was how similar what we saw was to man. As to giving PMN three hours after inoculation, timescales are compressed in small animals and we thought this was a good place to start. But again, it's a new model. We agree that it is hard to say what parameters constitute pre-treatment and post-treatment models here, but we will sort that out with time. In any case the fact that it is effective early is clear proof of principle that it might be effective later and we're very happy with that.
Dr. Leenan, thank you-the method that we used to homogenize lung releases bacteria from PMN and live intracellular bacteria will then grow out on the plates. So that may be a reasonable technical concern with some methodologies but we don't think it is an issue here.
